May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Self-Complementary Adeno-Associated Viruses (scAAV) Transduce Anterior Segment Tissues of Living Rats and Monkeys Without Detrimental Secondary Effects
Author Affiliations & Notes
  • L. K. Buie
    Ophthalmology, University of North Carolina, Chapel Hill, North Carolina
  • C. A. Rasmussen
    Ophthalmology & Visual Science, University of Wisconsin, Madison, Wisconsin
  • R. J. Samulski
    Gene Therapy Center, UNC, Chapel Hill, North Carolina
  • P. L. Kaufman
    Ophthalmology & Visual Science, University of Wisconsin, Madison, Wisconsin
  • T. Borras
    Ophthalmology, University of North Carolina, Chapel Hill, North Carolina
  • Footnotes
    Commercial Relationships L.K. Buie, None; C.A. Rasmussen, None; R.J. Samulski, None; P.L. Kaufman, None; T. Borras, None.
  • Footnotes
    Support NIH Grants EY11906, EY13126, EY15873, EY02698, NIH 1 P30 EY001665, OPREF, RRF (W Helmerich Chair), UW (P Duehr Chair) and RPB grants to UNC and UW.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 2050. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      L. K. Buie, C. A. Rasmussen, R. J. Samulski, P. L. Kaufman, T. Borras; Self-Complementary Adeno-Associated Viruses (scAAV) Transduce Anterior Segment Tissues of Living Rats and Monkeys Without Detrimental Secondary Effects. Invest. Ophthalmol. Vis. Sci. 2007;48(13):2050. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: Recombinant AAV viruses produce stable expression and elicit low immune response. scAAV are modified AAV which bypass the required second strand DNA synthesis to achieve transcription of the transgene. In contrast to conventional AAV, scAAV are able to transduce human trabecular meshwork (TM) in cultured cells and perfused organ cultures. Our goal is to obtain optimal, non immunogenic delivery of transgenes to the TM in a living system. Our purpose was to investigate scAAV transgene transduction in living rodents and non human primates.

Methods:: scAAV.GFP vector was prepared at the UNC vector core facility. Wistar rats received single dose intracamerally injection (6-8X109 viral particles, VP) of scAAV or vehicle. Intraocular pressures (IOP) (calibrated Tonometer and Tonopen) were taken at baseline and once a week thereafter. Animals were euthanized at 2, 5-7, and 9-10.5 wks post injection and their anterior segments processed for fluorescence histochemistry. Two cynomolgus monkeys received transcorneal injection of a 30 µl single dose (3X1010 VP). Follow-up examinations included IOP (Goldmann), slit lamp biomicroscopy, gonioscopy, fundus camera and microscope/cooled-CCD camera photography to detect GFP fluorescence.

Results:: Rats: scAAV injected eyes showed no clinical signs of inflammation or cataract formation. Whole mounts and cryosections showed intense GFP transduction to the iris, TM, and some corneal endothelium. Successful, GFP positive injections occurred in all eyes at 2 wks, in 13 out of 14 at 7 wks, and in 17 out of 18 at 2.5 months (last point tried). Delta-IOP values were not significantly different from baseline and/or from eyes injected with vehicle. Monkeys: At abstract submission, 2 wk post-injection, in vivo gonioscopic examination revealed strong fluorescence in the anterior ciliary muscle / iris processes / uveal meshwork, and in the pupillary iris sphincter in both animals. Slit lamp biomicroscopy revealed no visible inflammatory reaction in the scAAV treated eyes. IOP measurements remained similar between the eyes. Further follow-up over the next few months will be presented.

Conclusions:: scAAV is the first adeno-associated vector shown to transduce the living animal iris and trabecular meshwork. Because of the long term, non immunogenic transgene expression history of AAV vectors in eye diseases of the retina, scAAV holds good promise for developing gene transfer/gene therapy regimens to the TM.

Keywords: gene transfer/gene therapy • anterior segment • trabecular meshwork 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×